Parsippany Chapter Upcoming Events Join PCCI

 

Artemis Biomedical Technologies

A noninvasive technology company

Presenter: Keith Keeling, President and CEO of Artemis

 

Monday, June 9, 2014

Embassy Suites, Chesterbrook, Pennsylvania (directions)

 

About

 

CREATING VALUE WITH NONINVASIVE BLOOD DIAGNOSTICS TECHNOLOGY

 

Noninvasive blood glucose measurement is a disruptive technology that will transform the current $9 billion annual market for meters and disposable test strips and forever change the way millions of people living with diabetes manage the disease. Artemis Biomedical Technologies has an exclusive license to the intellectual property for a noninvasive technology to measure the concentration of selected blood analytes without a blood sample. The licensed intellectual property previously led to the development and manufacture of a noninvasive glucose monitor in pilot production quantities for clinical trials. Patient data compiled during clinical trials using the device (the D2K) demonstrated noninvasive measurement of glucose within the acceptable accuracy range of less than plus or minus 15% error. This degree of accuracy is as good or better than FDA approved devices currently on the market requiring a blood sample and a disposable for each measurement.

 

ABT's mission is to enable patients the option of unlimited daily testing to achieve better control of the disease by eliminating the pain of drawing blood and the incremental cost of single use disposables for each measurement. Diabetic patients currently monitoring glucose levels 4 to 6 times per day or more to effectively manage the disease represent a $4.6 billion annual market segment for disposable test strips. Detailed plans for engineering and design modifications to miniaturize the proven technology of the D2K to a handheld consumer device that will accurately measure the concentration of blood glucose noninvasively are in progress.

 

 

3 Major Issues

 

  1. The Artemis noninvasive glucose meter represents a significant improvement in the effective management of diabetes by allowing the patient to monitor blood glucose without drawing blood or incurring the incremental cost per measurement. What impact will noninvasive measurement have on market penetration? Can it be expected to encourage more frequent testing? And is it likely that tighter control of glucose concentration will in turn decrease the long-term complications of the disease and improve patient outcomes?
  2. The original desk-top D2K noninvasive glucose meter performed well within FDA standards in clinical trials for accuracy of glucose measurement. We have developed a new and improved version that features significant reductions in the size and power consumption in a handheld, battery operated unit. What is the best way to position these improvements in order to raise funds to manufacture a prototype and obtain FDA approval?
  3. What are the best channels and approaches to access patients, the medical community, strategic partners and investors to create awareness of our technology and the benefits to people living with diabetes?  

 

Program:

 

6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)

8:00 - Keith Keeling, President and CEO of Artemis, will deliver the Company's "Elevator" Pitch to the Group

8:20 - Panel will address three major issues crucial to helping the Company reach the next level.

9:00 - Open discussion: members and guests

 

 

Available Media

Please note: All information obtained here is the property of those presenting and should not be copied or duplicated without written consent.

 

Slides

None available at this time

Audio

None available at this time

Video

None available at this time

Webcast

Artemis Biomedical Technologies Webcast - 06/09/14

Contact Info:

 

 

 

Our Sponsors

EisnerAmperIdeas x Innovation Network i2nNew Jersey Institute of TechnologyScience Center

 

<Top of the page>

 

 

 

 

Questions or Coments?

Contact: Peter van der Kam,

peter@rxpcci.com | (610) 296-8086

 

 

 

Good Company! Good Drink! Good Food! Good Program! Good Fun!

 

Site Navigation

HOME  |  ABOUT PCCI  |   MAP / DIRECTIONS  |   JOIN US  |   BOARD MEMBERS  |   AFFILIATES  |  NEXT MEETING  |  ARCHIVES  |  PROFILES

CALENDAR OF EVENTS  |  PARSIPPANY CHAPTER  |  FEEDBACK / COMMENTS  |   CONTACT US

Pharmaceutical Consulting Consortium International, Inc.,

info@rxpcci.com or (610) 296-8086

Meetings Held at Embassy Suites - Valley Forge

888 Chesterbrook Blvd, Chesterbrook, Pennsylvania 19087

All content on this website is copyrighted and should not be reproduced without the consent of PCCI.

© Copyright 2016-2017

 

 

Tat Communication Inc